Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Acquire Antibody Maker Zymed for $60M

NEW YORK, Jan. 10 (GenomeWeb News) - Invitrogen plans to acquire antibody manufacturer Zymed Laboratories for $60 million in cash, the company said today.

 

Zymed, based in South San Francisco, offers immunoassay reagents for research and clinical diagnostics. The company has more than 2,000 antibodies and related products suitable for research in the areas of cancer, neurological diseases, and infectious disease.

 

Following the acquisition, which is expected to close by the end of February, Zymed's South San Franciscofacility will become the main site for Invitrogen's antibody production and distribution.

 

Invitrogen expects Zymed to generate $15 million in sales during the first year following the acquisition.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.